Refine by
Cardiology Articles & Analysis
197 news found
Understanding that different therapeutic areas have unique challenges, the company adapts its services to cater to fields like oncology, neurology, and cardiology, among others. This flexibility ensures that their technology answers the specific needs of each research project, providing bespoke solutions that align with distinct research goals. ...
“This is an important milestone that amplifies our reach and validates our mission to bring digital innovation to cardiology. By deepening our relationship with AWS, we can help even more clinicians improve cardiac care by delivering cutting-edge solutions that enable more efficient and effective remote monitoring,” said Jon Hunt, PhD., Implicity’s Chief ...
The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. ...
ByBayer AG
Englese has more than 20 years of experience in domestic and international commercial functions at biopharmaceutical companies across a breadth of therapeutic areas such as pain management, cardiology, liver disease, anesthesia and critical care. Prior to joining Tris Pharma, he was the chief commercial officer at Aziyo Biologics, where he oversaw multiple business units, ...
” Daxor’s BVA test has been associated with a reduction in heart failure 30-day mortality by 82%, 30-day readmissions by 56%, and 1-year mortality by 86% in a peer-reviewed study published in the Journal of the American College of Cardiology – Heart Failure titled “Heart Failure Outcomes With Volume Guided ...
The final data from this study were presented at the American Congress of Cardiology’s 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC). ...
ByBayer AG
These skills can boost your career whether you specialize in oncology, immunology, cardiology, neurology, diabetes, or any other rare disease and therapeutic area. ...
Results from the pivotal Phase III FIGARO-DKD study were presented at the European Society of Cardiology (ESC) Congress 2021 and simultaneously published in the New England Journal of Medicine. ...
ByBayer AG
Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. ...
Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. ...
The products of four hydrogel companies Sawhney founded with his partner Fred Khosravi (within their accelerator Incept LLC), have treated more than five million patients across the ophthalmic, surgical, interventional cardiology, and prostate cancer specialties. Sawhney founded Confluent Surgical in 1998, which, after proving out a hydrogel platform for surgical sealants and ...
Results from the pivotal Phase III FIGARO-DKD study were presented at the European Society of Cardiology (ESC) Congress 2021 and simultaneously published in the New England Journal of Medicine. ...
ByBayer AG
Earlier this month, Osso VR was included on TIME’s Best Inventions of 2022 list and partnered with the American College of Cardiology—underscoring the market’s rising demand for innovative, scalable surgical training tools. ...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
The study, published in the Journal of the American Medical Association in 2018 and conducted at the Scripps Research Translational Institute in partnership with Aetna and Janssen Pharmaceuticals, found that Zio XT-based screening was associated with increased detection of AFib, greater use of outpatient cardiology care, and a higher rate of initiation of stroke prevention ...
Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals. ...
Daxor entered an industry partnership with MedAxiom, an American College of Cardiology company, to amplify awareness and adoption of Daxor’s BVA technology among MedAxiom’s clinical members which includes C-suite executives and decision-makers from leading hospital systems looking to improve quality metrics that BVA technology addresses head-on – readmissions, ...
Until now, the only way to remove a mass from the heart was via open heart surgery, which the St. Cloud Hospital cardiology team deemed too risky for the patient. During a regular internal conference with the structural heart, heart failure and surgical teams, they brought up the case to brainstorm ideas on how to solve the problem, and one plausible idea was to find a ...
Daxor recently announced in July that it has entered an industry partnership with MedAxiom, an American College of Cardiology company, to amplify awareness and adoption of Daxor’s blood volume analysis (BVA) technology among MedAxiom’s clinical members. ...
The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. ...
ByBayer AG